Andrew McMillan, Ph.D. joined 5AM Ventures in 2005 from NASA, where he was a Principal Investigator in the Bioengineering Branch and the Center for Nanotechnology at the Ames Research Center. Dr. McMillan's research contributions in the areas of nanotech and biomaterials have resulted in five patents and nineteen publications in leading peer-reviewed journals, including Nature Materials, JACS and PNAS, and have been featured in US News & World Report,Scientific American, New Scientist, and AIChE Journal. Dr. McMillan represents 5AM working closely with the following portfolio companies:Achaogen, Ambrx, KaloBios Pharmaceuticals, Pearl Therapeutics,PhaseRx, Rennovia and Wildcat Discovery Technologies.Dr. McMillan holds a B.S. in Chemistry from UNC-Chapel Hill and a Ph.D.in Chemistry from Emory University, where he earned department honors for his research in biomaterials for drug delivery and tissue engineering. Dr. McMillan is based in the Menlo Park, CA office.
C. Robert Kidder will serve as a director following the completion of this offering. Mr. Kidder has served on numerous boards of directors including as: director of Merck and Co., Inc. from 2005 to 2017, non-executive Chairman of the Board of Chrysler Group LLC from 2009 to 2011, Chairman of Borden Inc. from 1995 to 2004, Chairman of Duracell International Inc. from 1988 to 1994 and director of Morgan Stanley from 1997 to 2017, including as Lead Director for eight years. Mr. Kidder currently serves as Chairman the board of directors of Advanced Drainage Systems, Inc. and Microvi Biotech Inc., serves on the board of Wildcat Discovery Technologies, Inc. and previously served on the board of directors of Schering-Plough Corporation from 2005 to 2009. He co-founded and served as Chief Executive Officer of 3Stone Advisors LLC, a private investment firm, from 2006 to 2011. Mr. Kidder was a Principal and Partner at Stonehenge Partners, Inc., a private investment firm, from 2004 to 2006. Prior to Stonehenge, Mr. Kidder served as President of Borden Capital, Inc., a company that provided financial and strategic advice to the Borden, Inc.’s family of companies, from 2001 to 2003. He served as Chief Executive Officer from 1995 to 2002 of Borden Chemical, Inc. (formerly Borden, Inc.), a forest products and industrial chemicals company. Mr. Kidder was also Chief Executive Officer and President of Duracell International Inc. Prior to joining Duracell, Mr. Kidder was Vice President, Planning and Development at Dart Industries Inc., worked as a general management consultant with McKinsey & Co. and served as an officer in the U.S. Navy Civil Engineer Corps. Mr. Kidder earned a B.S. in industrial engineering from the University of Michigan and a graduate degree in industrial economics from Iowa State University.
Peter Schultz is the Director of the Genomics Institute of the Novartis Research Foundation and a Scripps Professor of Chemistry at The Scripps Research Institute. Dr. Schultz graduated summa cum laude from the California Institute of Technology in 1979 from which he received his Ph.D. in 1984, working with Professor Peter Dervan. He then spent a year at the Massachusetts Institute of Technology with Professor Christopher Walsh before moving to the University of California, Berkeley and the Howard Hughes Medical Institute. Dr. Schultz has made several major scientific contributions, including the discovery of catalytic antibodies, using a methodology that for the first time expands the genetic codes of living organisms, and the development and application of combinatorial methods in chemistry and biology, including the first generation of combinatorial materials libraries. Dr. Schultz has received numerous awards, including the National Science Foundation's Alan T. Waterman Award (1988 ), the ACS Award in Pure Chemistry (1990), the Wolf Prize in Chemistry (1994), and the Paul Ehrlich Prize (2002). He has been a member of the National Academy of Sciences since 1993 and has also been a member of the Institute of Medicine of the National Academy of Sciences since 1998. Dr. Schultz is active on many editorial and scientific advisory boards. Dr. Schultz is a founding scientist of Affymax Research Institute and co-founder of Symyx, Syrrx, Kalypsys, Phenomix, Ambrx, Ilypsa and Wildcat Discovery.
Experienced Chairman with a demonstrated history of working in the biotechnology industry. Skilled in Business Planning, Investor Relations, Entrepreneurship, Venture Capital, and Deal Sourcing. Strong entrepreneurship professional graduated from Capital University.